Press

Communiqué presse immunothérapie

Survival rates of dogs with lymphoma multiplied by 5,6

May 2019. Urodelia, a French research company focused on the development of a therapeutic cancer vaccine, and a team of Italian veterinary researchers publish promising results issued of 6 years of treatment of 300 dogs that show a survival rate compared to conventional chemotherapy that can be multiplied by 5.6 on targeted diseases.

urodelia développe un vaccin anti cancer

Urodelia, AT THE HEART OF RESEARCH ON THERAPEUTIC VACCINES IN IMMUNO-ONCOLOGY

February 2019. Urodelia, a French research company focused on the development of a therapeutic vaccine in
oncology, is seeking to raise 2.5 million euros in 2019 to deploy its technology in veterinary
oncology and fund human health research. Its needs 6 million euros over 3 years.

urodelia italie vaccin anti cancer

A new therapeutic approach against dog B lymphoma

Italy, 2014. Press release in French and Italian